PFAS in Pharmaceuticals: A Patient-Centered Approach to Regulation

PFAS in Pharmaceuticals: Balancing Regulation and Patient Access

The proposed restriction of per- and polyfluoroalkyl substances (PFAS) in Europe is rapidly becoming one of the most significant regulatory discussions affecting the pharmaceutical industry. While environmental protection remains a shared and essential objective, the potential impact of a broad PFAS ban on medicines requires careful evaluation.

Recent developments (including the ongoing discussions within the European Chemicals Agency (ECHA) and the Socio-Economic Analysis Committee (SEAC)) highlight the urgency of defining a balanced, science-based strategy that protects both the environment and patient access to medicines.

Why are PFAS Critical in Pharmaceuticals

PFAS are widely used across pharmaceutical manufacturing processes due to their unique chemical stability, resistance, and performance characteristics. Their applications extend far beyond active pharmaceutical ingredients (APIs) and include:

• Manufacturing equipment and piping
• Process utilities and filtration systems
• Packaging components
• Drug delivery devices
• Excipients and formulation components

This widespread use makes PFAS substitution significantly more complex than in other industries. According to a joint industry survey, 1,922 active substances could be impacted by PFAS restrictions, with 93% of APIs produced in facilities relying on PFAS-based equipment and consumables. Only 7% of APIs actually contain PFAS within their molecular structure, demonstrating that the majority of the challenges relate to manufacturing infrastructure rather than product formulation alone. Furthermore, 674 of these medicines are included in the WHO Essential Medicines List, highlighting the potential risk to global patient access if restrictions are implemented without appropriate transition strategies.

The Risk of Supply Disruptions and Drug Shortages

A broad PFAS restriction could create significant challenges for pharmaceutical manufacturing in Europe. Industry stakeholders warn that such measures may lead to:

• Disruption of manufacturing processes
• Delays in regulatory approvals
• Increased production costs
• Supply chain instability
• Potential medicine shortages

These concerns are particularly relevant in the context of ongoing European initiatives aimed at strengthening strategic pharmaceutical autonomy and reducing dependency on external supply chains.

Recent EU policy discussions -including the Critical Medicines Act and initiatives addressing medicine shortages- emphasize the need to reinforce manufacturing resilience. A rapid PFAS ban could contradict these objectives and create unintended consequences for healthcare systems.

Why PFAS Substitution in Pharma is Not Straightforward

Unlike many other industries, pharmaceutical manufacturing operates within a highly regulated environment. Any modification involving PFAS removal may trigger extensive regulatory and technical requirements, including:

• Reformulation and material replacement
• Supplier qualification
• Analytical method redevelopment
• Stability studies
• Process validation
• Regulatory variations
• Manufacturing requalification

Each of these steps requires significant time and regulatory coordination. A sudden transition without a clear roadmap risks compromising both supply continuity and patient safety. This is why many industry stakeholders advocate for a risk-based and phased approach to PFAS regulation in pharmaceuticals.

Balancing Environmental Sustainability and Patient Care

The pharmaceutical sector strongly supports environmental sustainability and recognizes the importance of reducing PFAS exposure. However, policymakers must consider the unique characteristics of medicine manufacturing.

A patient-centred approach which combines environmental responsibility with realistic transition timelines is essential to avoid unintended consequences. The objective should not be simply eliminating PFAS, but ensuring a structured and sustainable transition that maintains uninterrupted access to critical therapies.

Supporting the Transition: a Strategic Quality and Testing Partner

As pharmaceutical companies navigate this evolving regulatory landscape, the need for integrated expertise is becoming increasingly critical. At Mérieux NutriSciences | Pharma & Healthcare, we enable pharmaceutical companies to maintain uncompromised quality while accelerating speed, efficiency, and resilience in a volatile environment. We go beyond compliance to drive faster batch release, greater reliability, and stronger end-to-end value chain performance.

Pharmaceutical companies are operating in an environment defined by unprecedented volatility. Geopolitical tensions, fragile supply chains, evolving regulatory expectations, and rapid technological advancements are fundamentally reshaping global manufacturing networks. To remain competitive, organizations must navigate a dual imperative: ensuring uncompromised product quality while continuously enhancing speed, efficiency, and operational resilience.

An Integrated One-Stop Shop for Complex Transitions

We operate one of Europe’s largest integrated testing campuses, delivering scale, expertise, and data continuity across the product lifecycle. Our centralized model enhances resilience, accelerates execution, and supports sustainable performance in a volatile environment. With more than 800 analysts and over 60 analytical techniques qualified under GxP environments, we provide a fully integrated testing ecosystem where multiple analytical activities are coordinated within a structured framework.

By centralizing capabilities, we enable pharmaceutical companies to benefit from:

• Greater data continuity
• Faster execution
• Improved coordination
• Enhanced operational reliability
• Stronger supply chain resilience

In today’s complex economic and geopolitical landscape, pharmaceutical companies face increasing pressure to secure supply chains, accelerate time-to-market, and maintain uncompromised quality standards. Our integrated model supports sustainable performance and long-term operational stability.

Conclusion: a Strategic and Patient-centered Path Forward

The PFAS debate represents a pivotal moment for the pharmaceutical industry. Environmental responsibility and patient access must advance together. A science-based, phased, and patient-centred approach will be essential to ensure that regulatory evolution strengthens—rather than disrupts—the pharmaceutical ecosystem.

Author:
Emanuele Conte
Pharma & Healthcare Business Unit Director